INDUSTRY EXPERT ARTICLES

This Valentine’s Day, get clued up on the allergens you might not have considered, and avoid leaving your date — or yourself — in hives, fits of sneezes, or potentially an even more serious condition on this special day.

The New York Times calls Dr. Frank Veith "an unlikely radical…waging an aggressive fight in the clubby world of the medical profession" for his tireless advocacy of patients and medical progress instead of the hospital's bottom line—no matter the consequences. The Medical Jungle will inspire anyone who faces adversity at any level to stand up and be radical, even when it is unpopular.

The Centers for Disease Control reports that heart disease is responsible for 25% of all deaths in the United States. It also reports that the condition accounts for $219 billion in healthcare costs and lost productivity. The statistics look grim, but advances in machine learning put hope on the horizon. Read on.

With so many patients already leveraging smartwatches and other devices to proactively monitor their health, practices can implement tools that mimic that convenience. The tools can then transfer the data electronically with minimal disruption to the patient and provider experience. Read more.

Smith writes, "The use of health apps has increased considerably in recent years. In 2018, there were 62.7 million monthly health app users in the United States. Just three years later, in 2021, that number jumped to 86.3 million monthly users. Likewise, the number of consumers willing to wear smart fitness technology has more than tripled in the last four years, from 9 percent to 33 percent of U.S. consumers."

Demetria Thomas shares her views the importance of evaluating ergonomic features of medical imaging equipment.

Athanase Kollias founded KINVENT - to bring objective, precise biofeedback data into the physical therapy space. Read what he has to say about the many benefits and advantages for care providers and patients alike

Mr. Bogner writes, "While the challenge of treating cardiovascular disease is daunting, I am optimistic about the progress we have made by developing a revolutionary MedTech device that will provide a solution for patients with privilege and without. I am looking forward to the next milestone of our first human use trials in Europe in early 2023." Read more what he has to say.

The potential of voice biomarkers is advancing and opening new opportunities for diagnoses, risk prediction, clinical outcomes, and symptomology.  As one of the most promising digital healthcare sectors, all age cohorts, especially the aging population, may see the most benefit. Read what Mr. Tal has to say.